IntelGenx Technologies Corp. (OTCMKTS:IGXT) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Saturday.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of IntelGenx Technologies Corp. in a research report on Tuesday.

IntelGenx Technologies Corp. (OTCMKTS:IGXT) opened at $0.71 on Friday. IntelGenx Technologies Corp. has a twelve month low of $0.62 and a twelve month high of $1.09. The company has a quick ratio of 2.65, a current ratio of 2.65 and a debt-to-equity ratio of 1.53.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/25/intelgenx-technologies-corp-igxt-cut-to-sell-at-valuengine.html.

About IntelGenx Technologies Corp.

IntelGenx Technologies Corp. is a drug delivery company focusing on the development of orally administered drug delivery products based on its oral drug delivery technologies. The Company is a provider of product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for IntelGenx Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies Corp. and related companies with MarketBeat.com's FREE daily email newsletter.